Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety

Ryan Abbott

Southwestern Law School; David Geffen School of Medicine at UCLA

99 Iowa L. Rev. 225 (2013)

Data on individual patients collected through state and federal health information exchanges has the potential to usher in a new era of drug regulation. These exchanges, produced by recent health care reform legislation, will amass an unprecedented amount of clinical information on drug usage, demographic variables, and patient outcomes. This information could aid the Food and Drug Administration (FDA) with post-market drug surveillance because it more accurately reflects clinical practice outcomes than the trials the FDA relies upon for drug approval. However, even with this data available, the market-driven impetus to use it to police drugs is weak. This is fixable; the post-market drug regulatory process needs new incentives to boost third party participation. While a variety of mechanisms could achieve this, the best option for generating robust results may be an administrative bounty proceeding that will allow third parties to submit evidence to the FDA to contest the claimed safety and efficacy profiles of drugs already on the market. This Article uses a case study of Merck’s former blockbuster drug Vioxx to demonstrate how this system might work. In creating a new incentive that counters the powerful financial motivation of drug manufacturers to obscure or misrepresent safety profiles, the proposed bounty proceeding could lead to an improved balance of the risks and benefits of drugs used by the American public. More broadly, this Article illustrates how to create an incentive for the private sector to supplement regulatory activity in a complex field.

Number of Pages in PDF File: 68

Keywords: medicine regulation, food and drug administration, public health, information systems

JEL Classification: D23, D78, H30, H51, I00, I18, K13

Accepted Paper Series

Download This Paper

Date posted: April 8, 2013 ; Last revised: November 5, 2013

Suggested Citation

Abbott, Ryan, Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety. 99 Iowa L. Rev. 225 (2013). Available at SSRN: http://ssrn.com/abstract=2246217

Contact Information

Ryan Benjamin Abbott (Contact Author)
Southwestern Law School ( email )
3050 Wilshire Blvd.
Los Angeles, CA 90010
United States
HOME PAGE: http://www.drryanabbott.com
David Geffen School of Medicine at UCLA ( email )
1000 Veteran Avenue, Box 956939
Los Angeles, CA 90095-6939
United States
Feedback to SSRN

Paper statistics
Abstract Views: 1,700
Downloads: 393
Download Rank: 39,533

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo6 in 0.406 seconds